EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Josef S SmolenRobert B M LandewéJohannes W J BijlsmaGerd R BurmesterMaxime DougadosAndreas KerschbaumerIain B McInnesAlexandre SeprianoRonald F van VollenhovenMaarten P T de WitDaniel AletahaMartin AringerJohn AsklingAlejandro BalsaMaarten BoersAlfons A den BroederMaya H BuchFrank ButtgereitRoberto CaporaliMario Humberto CardielDiederik De CockCatalin CodreanuMaurizio CutoloChristopher John EdwardsYvonne van Eijk-HustingsPaul EmeryAxel FinckhLaure GossecJacques-Eric GottenbergMerete Lund HetlandThomas Wj HuizingaMarios KoloumasZhanguo LiXavier MarietteUlf Müller-LadnerEduardo F MyslerJosé António Pereira Da SilvaGyula PoórJanet E PopeAndrea Rubbert-RothAdeline Ruyssen-WitrandKenneth G SaagAnja StrangfeldTsutomu TakeuchiMarieke VoshaarRené WesthovensDésirée Mfm van der HeijdePublished in: Annals of the rheumatic diseases (2020)
These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.